Details
Stereochemistry | ACHIRAL |
Molecular Formula | O2 |
Molecular Weight | 31.9988 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O=O
InChI
InChIKey=MYMOFIZGZYHOMD-UHFFFAOYSA-N
InChI=1S/O2/c1-2
Molecular Formula | O2 |
Molecular Weight | 31.9988 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Oxygen is a chemical element with atomic number 8. Diatomic oxygen constitutes 20.8% of the Earth's atmosphere. Diatomic oxygen is used by complex life forms such as animals, in cellular respiration. Medical oxygen is widely used in clinical practice to provide a basis for most modern anaesthetic techniques; to restore the tissue oxygen tension towards normal by improving oxygen availability in a wide range of conditions such as shock, severe haemorrhage, coronary occlusion, carbon monoxide poisoning, major trauma; to aid the resuscitation of the critically ill, when the circulation is impaired; to aid in neonatal resuscitation; to treat acute severe headache in adults diagnosed with cluster headache.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0009060 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24206183 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseNormobaric oxygen is widely recommended for patients with acute myocardial infarction. The randomized phase 3 clinical trial, however, did not demonstrate reduction in 1-year all-cause mortality compared to ambient air group. |
|||
Primary | Unknown Approved UseMedical oxygen is widely used in clinical practice to provide a basis for most modern anesthetic techniques; to restore the tissue oxygen tension towards normal by improving oxygen availability in a wide range of conditions such as shock, severe hemorrhage, coronary occlusion, carbon monoxide poisoning, major trauma. |
|||
Primary | Unknown Approved UseMedical oxygen is widely used in clinical practice to treat acute severe headache in adults diagnosed with a cluster headache. |
|||
Primary | Unknown Approved UseMedical oxygen is widely used in clinical practice to restore the tissue oxygen tension towards normal by improving oxygen availability in a wide range of conditions such as shock, severe hemorrhage, coronary occlusion, carbon monoxide poisoning, major trauma. |
PubMed
Title | Date | PubMed |
---|---|---|
Overexpression of manganese superoxide dismutase protects lung epithelial cells against oxidant injury. | 2001 Apr |
|
Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells. | 2001 Apr 15 |
|
Dependence of excitotoxic neurodegeneration on mitochondrial aconitase inactivation. | 2001 Aug |
|
Recovery from oxidant-mediated lung injury: response of metallothionein, MIP-2, and MCP-1 to nitrogen dioxide, oxygen, and ozone exposures. | 2001 Aug |
|
Role of protein kinase Cdelta in transmitting hypoxia signal to HSF and HIF-1. | 2001 Aug |
|
Activation of signal transducer and activator of transcription 3 protects cardiomyocytes from hypoxia/reoxygenation-induced oxidative stress through the upregulation of manganese superoxide dismutase. | 2001 Aug 28 |
|
Correlation of HO-1 expression with onset and reversal of hypoxia-induced vasoconstrictor hyporeactivity. | 2001 Jul |
|
Sensory nerves promote ozone-induced lung inflammation in mice. | 2001 Jul 15 |
|
Cobalt induces heme oxygenase-1 expression by a hypoxia-inducible factor-independent mechanism in Chinese hamster ovary cells: regulation by Nrf2 and MafG transcription factors. | 2001 Jul 20 |
|
Hypoxia regulates avian cardiac Arnt and HIF-1alpha mRNA expression. | 2001 Mar 30 |
|
Hypoxia-induced regulation of MAPK phosphatase-1 as identified by subtractive suppression hybridization and cDNA microarray analysis. | 2001 Nov 30 |
|
Poly(ADP-ribose) polymerase inhibitors attenuate necrotic but not apoptotic neuronal death in experimental models of cerebral ischemia. | 2001 Sep |
|
Hypoxic preconditioning induces changes in HIF-1 target genes in neonatal rat brain. | 2001 Sep |
|
Prevention of further cyclophosphamide induced hemorrhagic cystitis by hyperbaric oxygen and mesna in guinea pigs. | 2001 Sep |
|
Hypoxia increases leptin expression in human PAZ6 adipose cells. | 2002 Apr |
|
Role of mitochondrial oxidant generation in endothelial cell responses to hypoxia. | 2002 Apr 1 |
|
The dietary flavonoid quercetin modulates HIF-1 alpha activity in endothelial cells. | 2002 Apr 26 |
|
NADPH oxidase(s): new source(s) of reactive oxygen species in the vascular system? | 2002 Aug |
|
Response of VEGF expression to amino acid deprivation and inducers of endoplasmic reticulum stress. | 2002 Aug |
|
Growth inhibitory factor prevents neurite extension and the death of cortical neurons caused by high oxygen exposure through hydroxyl radical scavenging. | 2002 Aug 30 |
|
Increased migration of murine keratinocytes under hypoxia is mediated by induction of urokinase plasminogen activator. | 2002 Dec |
|
Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) activation suppresses ischemic induction of Egr-1 and its inflammatory gene targets. | 2002 Dec |
|
Airway chemotransduction: from oxygen sensor to cellular effector. | 2002 Dec 15 |
|
Reactive oxygen species and cell signaling: respiratory burst in macrophage signaling. | 2002 Dec 15 |
|
Hypoxia and beta 2-agonists regulate cell surface expression of the epithelial sodium channel in native alveolar epithelial cells. | 2002 Dec 6 |
|
Basic toxicological approach has been effective in two poisoned patients with amitraz ingestion: case reports. | 2002 Jan |
|
Stabilization of hypoxia-inducible factor-1alpha is involved in the hypoxic stimuli-induced expression of vascular endothelial growth factor in osteoblastic cells. | 2002 Jan 7 |
|
Oxygen therapy for infants with chronic lung disease. | 2002 Jul |
|
Reactive species mediated injury of human lung epithelial cells after hypoxia-reoxygenation. | 2002 Jul-Aug |
|
Endothelial nitric oxide synthase lies downstream from angiotensin II-induced angiogenesis in ischemic hindlimb. | 2002 Mar 1 |
|
Inhibitors of mitochondrial complex I attenuate the accumulation of hypoxia-inducible factor-1 during hypoxia in Hep3B cells. | 2002 May |
|
Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis. | 2002 May |
|
Adaptive responses to oxidative damage in three mutants of Caenorhabditis elegans (age-1, mev-1 and daf-16) that affect life span. | 2002 Nov |
|
Hyperbaric oxygen for cyclophosphamide-induced cystitis. | 2002 Nov |
|
Hypoxic but not anoxic stabilization of HIF-1alpha requires mitochondrial reactive oxygen species. | 2002 Nov |
|
The role of hypoxia-inducible signaling pathway in nickel carcinogenesis. | 2002 Oct |
|
Control of the hypoxic response in Drosophila melanogaster by the basic helix-loop-helix PAS protein similar. | 2002 Oct |
|
Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2). | 2002 Oct 25 |
|
Retinal oxygen: fundamental and clinical aspects. | 2003 Apr |
|
Vascular endothelial growth factor in the cerebrospinal fluid of infants who died of sudden infant death syndrome: evidence for antecedent hypoxia. | 2003 Feb |
|
Suppression of tumor necrosis factor-alpha by beta2-adrenoceptor activation: role of mitogen-activated protein kinases in renal mesangial cells. | 2003 Jan |
|
Oxygen-regulated expression of the Wilms' tumor suppressor Wt1 involves hypoxia-inducible factor-1 (HIF-1). | 2003 Jul |
|
Redox regulation of HIF-1alpha levels and HO-1 expression in renal medullary interstitial cells. | 2003 Jun |
|
Induction of T-type calcium channel gene expression by chronic hypoxia. | 2003 Jun 20 |
|
Use of helium-oxygen mixtures in the treatment of acute asthma: a systematic review. | 2003 Mar |
|
Heliox vs air-oxygen mixtures for the treatment of patients with acute asthma: a systematic overview. | 2003 Mar |
|
Hyperbaric oxygen for treating wounds: a systematic review of the literature. | 2003 Mar |
|
Oxygen administration in infants. | 2003 Mar |
|
The cellular oxygen tension regulates expression of the endoplasmic oxidoreductase ERO1-Lalpha. | 2003 May |
|
Cobalt inhibits the interaction between hypoxia-inducible factor-alpha and von Hippel-Lindau protein by direct binding to hypoxia-inducible factor-alpha. | 2003 May 2 |
Patents
Sample Use Guides
Medical oxygen is administered by inhalation through the lungs. The major exception is when a metered supply is fed into the oxygenator of an extracorporeal circulation of a cardiopulmonary by-pass system. For a cluster headache, oxygen should be administered as soon as possible after the onset of the attack, via a non-rebreathing facemask at a flow of 6 to 12 l/min for approximately 15 minutes.
Route of Administration:
Respiratory
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:22:01 GMT 2025
by
admin
on
Mon Mar 31 18:22:01 GMT 2025
|
Record UNII |
S88TT14065
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LOINC |
10236-8
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
LOINC |
19211-2
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
LOINC |
10248-3
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
JECFA EVALUATION |
INS-948
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
LOINC |
10242-6
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
LOINC |
10233-5
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
DSLD |
1363 (Number of products:4)
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
LOINC |
10240-0
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
LOINC |
2703-7
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
WHO-VATC |
QV03AN01
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
LOINC |
10245-9
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
WHO-ATC |
V03AN01
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
LOINC |
2705-2
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
LOINC |
10239-2
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
LOINC |
10235-0
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
LOINC |
10244-2
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
WHO-ESSENTIAL MEDICINES LIST | 1.1.1 | ||
|
LOINC |
10247-5
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
LOINC |
10232-7
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
LOINC |
3147-6
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
LOINC |
3148-4
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
LOINC |
10241-8
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
WHO-ESSENTIAL MEDICINES LIST | 1.4 | ||
|
LOINC |
10238-4
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
LOINC |
10234-3
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
LOINC |
11556-8
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
LOINC |
10243-4
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
LOINC |
2706-0
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
LOINC |
10226-9
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
LOINC |
10237-6
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
LOINC |
3149-2
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
LOINC |
14864-3
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
NCI_THESAURUS |
C1940
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
DSLD |
1827 (Number of products:15)
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
LOINC |
28648-4
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
LOINC |
10246-7
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
LOINC |
2704-5
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
LOINC |
28649-2
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL1234886
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
PRIMARY | |||
|
7782-44-7
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
PRIMARY | |||
|
100000090500
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
PRIMARY | |||
|
DTXSID2037681
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
PRIMARY | |||
|
7806
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
PRIMARY | RxNorm | ||
|
m8333
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
PRIMARY | Merck Index | ||
|
D010100
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
PRIMARY | |||
|
4235
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
PRIMARY | |||
|
OXYGEN
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
PRIMARY | Description: A colourless gas; odourless. Solubility: One volume dissolves in about 32 volumes of water and in about 7 volumes of ethanol (~750 g/l) TS, both at apressure of 101.3 kPa and 20?C. Category: Gas for inhalation. Storage: Oxygen should be kept as compressed gas or liquid at cryogenic temperature, in appropriate containers complying withthe safety regulations of the national authority. Valves or taps should not be lubricated with oil or grease. Labelling: An ISO standard1 requires that cylinders containing oxygen intended for medical use should bear the name of thecontents in legible and permanent characters and, preferably, also the molecular formula O2.1 International Standard 32. Gas cylinders for medical use - marking for identification of content. International Organization for Standardization, Switzerland, 1977. Additional information: In the analysis of medicinal gases certain tests are not intended for hospital pharmacists. They are solely applicable by laboratories equipped with the specialized apparatus. Requirements: Oxygen contains not less than 99.5% v/v of O2. | ||
|
S88TT14065
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
PRIMARY | |||
|
S88TT14065
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
PRIMARY | |||
|
231-956-9
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
PRIMARY | |||
|
977
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
PRIMARY | |||
|
15379
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
PRIMARY | |||
|
C722
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
PRIMARY | |||
|
5054
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
PRIMARY | |||
|
25805
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
PRIMARY | |||
|
Triplet oxygen
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
PRIMARY | |||
|
SUB14733MIG
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
PRIMARY | |||
|
DB09140
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
LABELED -> NON-LABELED |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|